Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19265483 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | July 2025 | August 2025 | Allow | 2 | 0 | 0 | No | No |
| 19184766 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | April 2025 | October 2025 | Allow | 6 | 0 | 1 | No | No |
| 19184838 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | April 2025 | November 2025 | Allow | 7 | 0 | 1 | No | No |
| 19184689 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | April 2025 | December 2025 | Allow | 8 | 0 | 1 | No | No |
| 18938926 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | November 2024 | May 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18771270 | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | July 2024 | December 2025 | Abandon | 17 | 1 | 1 | No | No |
| 18643330 | PEPTOID-BASED INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE (PRMT) FAMILY | April 2024 | April 2025 | Allow | 12 | 1 | 1 | No | No |
| 18643948 | METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES | April 2024 | February 2026 | Allow | 22 | 1 | 1 | No | No |
| 18630017 | Fluorogenic Probe Using a Mislow-Evans Rearrangement for Real-Time Imaging of Hydrogen Peroxide | April 2024 | October 2025 | Allow | 18 | 2 | 1 | No | No |
| 18618379 | SALT OF AN AMINOPYRIDINE DERIVATIVE COMPOUND, A CRYSTALLINE FORM THEREOF, AND A PROCESS FOR PREPARING THE SAME | March 2024 | July 2025 | Allow | 15 | 2 | 1 | Yes | No |
| 18617723 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | March 2024 | April 2025 | Allow | 13 | 0 | 1 | No | No |
| 18613641 | Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS) | March 2024 | January 2026 | Allow | 22 | 1 | 0 | No | No |
| 18612849 | COMPOUNDS AND THEIR USE | March 2024 | April 2025 | Allow | 13 | 0 | 1 | No | No |
| 18605248 | CDK2 INHIBITORS | March 2024 | September 2025 | Allow | 18 | 0 | 1 | No | No |
| 18421849 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | January 2024 | June 2025 | Allow | 17 | 0 | 1 | Yes | No |
| 18414865 | COMPOSITIONS AND USES THEREOF | January 2024 | January 2026 | Allow | 24 | 2 | 2 | No | No |
| 18545953 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | December 2023 | November 2025 | Allow | 23 | 0 | 0 | No | No |
| 18545932 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | December 2023 | July 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18520156 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | November 2023 | December 2024 | Allow | 13 | 1 | 2 | Yes | No |
| 18509586 | TARGETING THE TLK1/NEK1 AXIS IN PROSTATE CANCER | November 2023 | July 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18289449 | ORGANOMETALLIC COMPOUND AND APPLICATION THEREOF | November 2023 | February 2026 | Allow | 27 | 0 | 0 | No | No |
| 18501930 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | November 2023 | October 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18289437 | ORGANOMETALLIC COMPOUND AND APPLICATION THEREOF | November 2023 | January 2026 | Allow | 27 | 0 | 0 | Yes | No |
| 18385025 | NOVEL PROCESSES FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | October 2023 | November 2024 | Allow | 12 | 0 | 1 | No | No |
| 18482143 | Inhibitors of RAD52 Recombination Protein and Methods Using Same | October 2023 | August 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18476050 | SOLID FORMS AND COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF | September 2023 | August 2024 | Allow | 11 | 1 | 0 | No | No |
| 18465768 | COMPOSITIONS, KITS, AND METHODS TO INDUCE ACQUIRED CYTORESISTANCE USING STRESS PROTEIN INDUCERS | September 2023 | April 2024 | Allow | 7 | 1 | 1 | No | No |
| 18234608 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | August 2023 | August 2024 | Allow | 12 | 0 | 1 | No | No |
| 18365392 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | August 2023 | November 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18365044 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | August 2023 | January 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18351283 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | July 2023 | April 2025 | Allow | 21 | 1 | 1 | No | No |
| 18213082 | ANTITUMORAL COMPOUNDS | June 2023 | March 2025 | Allow | 21 | 1 | 1 | No | No |
| 18332566 | TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USE | June 2023 | May 2024 | Allow | 11 | 0 | 1 | No | No |
| 18254550 | SOLID STATE FORMS OF HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE | May 2023 | March 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18308037 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | April 2023 | July 2025 | Allow | 26 | 2 | 0 | No | No |
| 18136734 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | April 2023 | May 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18136661 | PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF | April 2023 | August 2024 | Allow | 16 | 0 | 1 | No | No |
| 18133060 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | April 2023 | December 2024 | Allow | 20 | 1 | 1 | No | No |
| 18124427 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | March 2023 | April 2024 | Allow | 13 | 1 | 1 | No | No |
| 18181099 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | March 2023 | July 2024 | Allow | 16 | 2 | 1 | No | No |
| 18172742 | BICYCLIC ENONE CARBOXYLATES AS MODULATORS OF TRANSPORTERS AND USES THEREOF | February 2023 | September 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18112402 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | February 2023 | January 2025 | Allow | 23 | 1 | 1 | No | No |
| 18166178 | CDK2 INHIBITORS | February 2023 | February 2024 | Allow | 12 | 2 | 1 | No | No |
| 18018359 | COMPOUNDS | January 2023 | March 2026 | Allow | 37 | 1 | 1 | No | No |
| 18099875 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | January 2023 | July 2024 | Allow | 18 | 0 | 1 | No | No |
| 18006068 | PROCESS FOR PREPARING AMINOFURANES | January 2023 | January 2026 | Allow | 36 | 1 | 1 | No | No |
| 18004837 | MIXTURE OF LEVONOGESTREL AND ETHINYLESTRADIOL AS CONTROL FOR BARK INSECTS | January 2023 | December 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 18002004 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | December 2022 | December 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17928519 | Nitrosation Reagents and Methods | November 2022 | June 2025 | Allow | 30 | 0 | 0 | No | No |
| 17999545 | DRUG-LIKE MOLECULES AND METHODS FOR THE THERAPEUTIC TARGETING OF VIRAL RNA STRUCTURES | November 2022 | January 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18049652 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | October 2022 | May 2024 | Allow | 18 | 1 | 1 | No | No |
| 18046011 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | October 2022 | May 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17959920 | ENANTIOMERS OF A2-73, ANALOGUES, AND SIGMA AGONIST ACTIVITY | October 2022 | September 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17953935 | CRYSTALLINE SALTS OF PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR | September 2022 | September 2023 | Allow | 12 | 0 | 1 | No | No |
| 17907174 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORS | September 2022 | February 2026 | Allow | 40 | 1 | 1 | No | No |
| 17907176 | 1,3-DIHYDRO-2H-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | September 2022 | February 2026 | Allow | 41 | 1 | 1 | No | No |
| 17930695 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | September 2022 | January 2025 | Abandon | 28 | 2 | 1 | Yes | No |
| 17929656 | METHODS OF TREATING GLIOBLASTOMA | September 2022 | January 2024 | Abandon | 17 | 0 | 1 | No | No |
| 17908362 | A PROCESS FOR PREPARATION OF 3,6-DICHLOROCYANO PYRAZINE, 3,6-DIOXOPIPERAZINE DERIVATIVES AND PRODUCTION OF FAVIPIRAVIR THEREOF | August 2022 | August 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17896767 | EBNA1 Inhibitor Crystalline Forms, and Methods of Preparing and Using Same | August 2022 | June 2024 | Allow | 21 | 1 | 1 | No | No |
| 17894700 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | August 2022 | November 2023 | Allow | 15 | 0 | 1 | No | No |
| 17816855 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | August 2022 | August 2024 | Allow | 24 | 1 | 1 | No | No |
| 17816281 | CXCR7 INHIBITORS FOR THE TREATMENT OF CANCER | July 2022 | March 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17870573 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | July 2022 | October 2023 | Allow | 15 | 0 | 1 | No | No |
| 17634361 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | July 2022 | August 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17777428 | BICYCLIC COMPOUND USED AS SELECTIVE ANDROGEN RECEPTOR MODULATOR | July 2022 | August 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17858233 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AGING-RELATED DISEASES | July 2022 | November 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17810367 | COMPOUNDS AND THEIR USE | July 2022 | March 2024 | Allow | 20 | 1 | 1 | No | No |
| 17790330 | CYCLOCARBONATE GROUP-CONTAINING (METH)ACRYLATE MONOMER AND POLYMER | June 2022 | November 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17855414 | METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES | June 2022 | January 2024 | Allow | 18 | 1 | 1 | No | No |
| 17850453 | CDK2 INHIBITORS | June 2022 | January 2024 | Allow | 18 | 1 | 1 | No | No |
| 17845534 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | June 2022 | January 2024 | Allow | 19 | 1 | 1 | No | No |
| 17845142 | BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS | June 2022 | February 2024 | Allow | 20 | 0 | 1 | No | No |
| 17845499 | Method of Manufacture for Liquid Cannabinoids, and Modified CBD Oil Composition | June 2022 | January 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17844921 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | June 2022 | February 2024 | Allow | 20 | 1 | 1 | No | No |
| 17843197 | COMPOSITIONS PROVIDING SLOW RELEASE OF CAFFEINE | June 2022 | April 2025 | Allow | 34 | 1 | 2 | No | No |
| 17842158 | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | June 2022 | November 2024 | Abandon | 29 | 2 | 1 | No | No |
| 17840957 | BCL-2 INHIBITORS | June 2022 | January 2024 | Allow | 19 | 1 | 1 | No | No |
| 17784239 | TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES | June 2022 | September 2025 | Allow | 40 | 1 | 1 | No | No |
| 17828643 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | May 2022 | September 2024 | Abandon | 27 | 1 | 2 | Yes | No |
| 17826289 | ORAL AQUEOUS SUSPENSION FORMULATION COMPRISING CARBAMATE COMPOUND | May 2022 | October 2024 | Allow | 29 | 2 | 1 | No | No |
| 17744432 | 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | May 2022 | July 2024 | Abandon | 26 | 2 | 1 | No | No |
| 17776952 | COMPOUNDS AND USES THEREOF | May 2022 | November 2024 | Allow | 30 | 1 | 1 | No | No |
| 17738872 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | May 2022 | May 2024 | Abandon | 25 | 1 | 2 | No | No |
| 17736057 | TIMOSAPONIN COMPOUNDS | May 2022 | October 2024 | Allow | 30 | 1 | 2 | No | No |
| 17661274 | USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATION AND AGING IN THE SKIN | April 2022 | November 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17771344 | Non-Coordinating Anion Activators Containing a Cation with Long Chain Alkoxy Functionalization | April 2022 | September 2025 | Allow | 41 | 1 | 1 | No | No |
| 17755100 | Process for preparing glycerol carbonate (meth)acrylate | April 2022 | June 2025 | Allow | 38 | 0 | 0 | No | No |
| 17726120 | METHODS, COMPOSITIONS, KITS AND USES THEREOF TARGETING AND/OR TREATING VRK2 TO ENHANCE EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITOR(S) | April 2022 | April 2025 | Allow | 35 | 2 | 1 | No | No |
| 17659104 | CLEANING COMPOSITION | April 2022 | October 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17716645 | P53-DESTABILIZING PROTEIN ASSOCIATED WITH PROTO-ONCOGENE STEMNESS AS A THERAPEUTIC TARGET AND INHIBITORS THEREOF FOR USE IN TREATMENT OF CANCER | April 2022 | March 2024 | Allow | 24 | 1 | 1 | No | No |
| 17754703 | QUINOLONE CARBOXYLIC DERIVATIVES | April 2022 | February 2025 | Allow | 35 | 0 | 0 | No | No |
| 17766601 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | April 2022 | January 2026 | Allow | 46 | 2 | 1 | No | No |
| 17713512 | APPLICATION OF HONOKIOL AND MAGNOLOL IN PREPARATION OF MCR-1 ENZYME INHIBITOR | April 2022 | February 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17714114 | Antitumoral Compounds | April 2022 | January 2023 | Allow | 9 | 1 | 1 | No | No |
| 17763073 | SILICONE DROPLETS | March 2022 | September 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17761868 | AN IMPROVED PROCESS FOR 4-(HYDROXYMETHYL)-5-METHYL-1,3-DIOXOL-2-ONE | March 2022 | April 2025 | Allow | 37 | 1 | 0 | No | No |
| 17697655 | SALT OF AN AMINOPYRIDINE DERIVATIVE COMPOUND, A CRYSTALLINE FORM THEREOF, AND A PROCESS FOR PREPARING THE SAME | March 2022 | September 2023 | Allow | 18 | 0 | 1 | Yes | No |
| 17655262 | FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOF | March 2022 | September 2024 | Abandon | 30 | 2 | 1 | Yes | No |
| 17760878 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | March 2022 | January 2025 | Abandon | 34 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner YOO, SUN JAE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 46.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner YOO, SUN JAE works in Art Unit 1621 and has examined 313 patent applications in our dataset. With an allowance rate of 84.7%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 37 months.
Examiner YOO, SUN JAE's allowance rate of 84.7% places them in the 60% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by YOO, SUN JAE receive 1.70 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by YOO, SUN JAE is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +19.4% benefit to allowance rate for applications examined by YOO, SUN JAE. This interview benefit is in the 62% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 29.7% of applications are subsequently allowed. This success rate is in the 57% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 45.5% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 78.8% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 30.4% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 12.1% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.